To Investigate The Effect Of 3TC Against HBV Combinationg With Ara-AMP

Although with the development of the research of antiviral drug, there aren't ideal antiviral drug for treatment to the patients with chronic HBV infection. The curative effect of mono-therapy is not satisfactory for it is tend to relapse and produce drug-resistance, combination therapy is one of the main research direction now. our study investigate the efficacy of 3TC against HBV combination with Ara-AMP in vivo and vitro. Follows are the main contents.1. 2.2.15 cell line was used as HBV infection cell to be respectively cultured with 3TC and Ara-AMP (combination group), 3TC (3TC group) or Ara-AMP (Ara-AMP group) alone for 8 days. Then HBeAg> HBsAg in cell supernatant and intracellular HBV DNA were respectively measured by radioimmunological method and dot blot assay. The concentration in the combination group has no toxicity to cells. The inhibitive effect to HBeAg has not been enhanced obviously in combination group. Compared with using the same concentration 3TC alone, the inhibitive ratio against HBsAg ofAra-AMP 50ug/ml combined with 3TC 1.25ug/ml and 5.Dug/ml respectively were higher. When 3TC 5.0ug/ml was combined with Ara-AMP 12.5 ug/ml and 50 ug/ml respectively, the inhibitive ratio against HBV DNA (45.9%, 50.36%) was higher than the groups treated with the same concentration 3TC and Ara-AMP alone. The difference were significant (p<0.05). This results indicated that combination of 3TC with Ara-AMP could enhance the inhibitive efficacy against HBsAg and HBV DNA.2. 82 patients with chronic hepatitis B were random divided into three groups in clinic. Group one had 22 patients treated with combination of 3TC and Ara-AMP. Group two and group three respectively had 28 and 32 cases treated with 3TC and Ara-AMP alone. At the end of therapy the normal ratio of ALT has no difference in the three groups. However, the negative conversion ratio of serum HBV DNA (68.2%) in the group one is higher than group there (31.3%), and the negative conversion ratio of serum HBeAg (36.3%) is higher than group tow (21.4%). The adverse response is same in group one and group two. This results indicated that treatment with Ara-AMP combined with 3TC is safe and endurable. The negative conversion ratio of serum HBV DNA by combination therapy is higher than Ara-AMP therapy , and the negative conversion ratio of serum HBeAg is higher than 3TC therapy. But the difference has no significance.